Mabtech, a global provider of advanced immunoassays, and Sai Life Sciences, an integrated Contract Research, Development, and Manufacturing Organization (CRDMO), have announced a strategic collaboration to establish Sai’s Boston laboratory as a co-marketed execution and demonstration hub for the Mabtech EYRA™ platform.
Under the partnership, Mabtech and Sai will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine analysis and phenotyping workflows powered by the EYRA platform at Sai’s Boston discovery site.
The collaboration aims to accelerate access to next-generation immune profiling capabilities for biopharma and biotech companies working in immuno-oncology, vaccines, inflammation, and cellular therapies.
The EYRA platform features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously in a single run with minimal hands-on time. Developed through a long-term research collaboration, EYRA addresses limitations of traditional flow- and plate-based systems, enabling scalable, streamlined immune profiling workflows.
Key components of the collaboration include joint delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations and pilot programs at the Boston site, shared thought leadership and case study development, and integrated business development support for discovery through translational research.
The initiative positions Sai’s Boston laboratory as a US hub for EYRA-enabled immunology workflows, strengthening its capabilities to support complex immunology and immuno-oncology programs while integrating advanced immune profiling into broader discovery and translational strategies.
Also Read